抄録
The effect of pyridinolcarbamate treatment in atherosclerosis obliterans was evaluated in 47 patients during a double-blind crossover trial using the mean of crest time from toe plethysmography.
After the initial 3 weeks of placebo washout a 10 week regimen of placebo or pyridinolcarbamate (1.5Gm. daily) and another 10 week of alternative regimen were given successively.
1) Twenty-two cases completed the trial and after the pyridinolcarbamate regimen the prolonged crest time was improved in 8 out of total 44 legs (18.2%), no change in 36 (81.8%) and worsening in none. After the placebo regimen, there was improvement in none, no change in 37 out of 44 legs (84.1%) and worsening in 7 (15.9%). This difference was statistically significant (p<0.005).
2) The crest time before treatment was tabulated by the location of arterial obstruction; aorto-iliac 0.39±0.033sec., femoropopliteal 0.35±023sec. and arteries in lower leg 0.31±0.026sec. Crest time in patients with aorto-iliac obstruction was more prolonged than in femoro-popliteal, which in turn was more prolonged than in more distal leg obstruction, but these differences were not statistically significant (p<0.10).
3) Pyridinolcarbamate treatment reduced the prolonged crest time more than placebo treatment even in dropout patients (p<0.005).
4) There was no difference in side effects among pyridinolcar-bamate and placebo trial except the one case which showed transient SGOT and SGPT elevation during pyridinolcarbamate treatment.
Our observations show that pyridinolcarbamate exerts a favorable effect in patients suffering from atherosclerosis obliterans.
